Technology
Positive
Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors
Breaking news from global financial markets
il y a 3 jours
Lire Plus
il y a 3 jours
4,082
il y a 3 jours
3,577
il y a 3 jours
3,340
il y a 3 jours
2,273
il y a 3 jours
2,256
il y a 3 jours
1,747
il y a 3 jours
4,829
il y a 3 jours
1,060
il y a 3 jours
4,009
il y a 3 jours
1,759
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Technology
il y a 3 jours
4,254
il y a 3 jours
4,586
il y a 3 jours
2,732
Tendances Actuelles
1
IO DeFi Launches New Mobile App, Making BTC and XRP Hashrate Earnings Accessible...
28,347
il y a 23 heures
2
BPCE : Mise à disposition du troisième amendement au document d’enregistrement u...
38,356
il y a 23 heures
3
AVTR Investors Have Opportunity to Lead Avantor, Inc. Securities Fraud Lawsuit w...
11,258
il y a 1 jour
4
BTCC November 2025 Product Update: Exchange Introduces Futures Pro Copy Trading
42,130
il y a 1 jour
5